| Not Yet Recruiting | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC NCT07392073 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases NCT07481786 | Sun Yat-sen University | Phase 3 |
| Recruiting | Engagement of Veterans With Lung Cancer NCT07219251 | Palo Alto Veterans Institute for Research | N/A |
| Recruiting | Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer NCT07423169 | Karl Landsteiner University of Health Sciences | N/A |
| Not Yet Recruiting | SL-28 for Advanced Solid Tumours NCT07341737 | Second Life Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC NCT07416058 | Guangdong Association of Clinical Trials | Phase 2 |
| Not Yet Recruiting | Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teachi NCT07373171 | Tribhuvan University, Nepal | N/A |
| Not Yet Recruiting | ADH1B and ALDH Gene Variants and Lung Cancer Risk NCT07273279 | Kaohsiung Medical University | — |
| Recruiting | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocar NCT07235280 | Jonsson Comprehensive Cancer Center | EARLY_Phase 1 |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Not Yet Recruiting | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT NCT07169903 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 3 |
| Recruiting | SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors NCT07161713 | Barbara Nemesure | N/A |
| Recruiting | Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT NCT07479095 | Fondazione del Piemonte per l'Oncologia | N/A |
| Recruiting | Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients NCT07012759 | Fu Jen Catholic University | — |
| Not Yet Recruiting | Orlistat Overcoming Third-generation EGFR-TKI Resistance NCT06818955 | Ping Peng | Phase 2 |
| Not Yet Recruiting | Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy NCT06602661 | Surrey Thoracic Surgery Group | Phase 1 |
| Active Not Recruiting | Comparison Paravertebral and Serratus Anterior Plane Block in Video-assisted Thoracoscopic Surgery. NCT07002788 | Hacettepe University | N/A |
| Recruiting | WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma NCT05925764 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Recruiting | Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors NCT06843629 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Not Yet Recruiting | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor NCT06619886 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Recruiting | Segmentectomy for Solid-dominant Lung Cancer NCT06634966 | Fudan University | Phase 3 |
| Recruiting | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846 | Hunan Province Tumor Hospital | Phase 2 |
| Recruiting | Lymph Node Pathologic Grading Strategy NCT06745830 | Fudan University | — |
| Completed | DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma NCT06477211 | Nanjing University | — |
| Withdrawn | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pa NCT04870034 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Unknown | Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarc NCT06104709 | China-Japan Friendship Hospital | — |
| Recruiting | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors NCT05887492 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic NCT06056115 | Hebei Medical University Fourth Hospital | N/A |
| Recruiting | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1 NCT06031246 | Fudan University | Phase 3 |
| Recruiting | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Fr NCT06031181 | Fudan University | Phase 3 |
| Recruiting | Shared Decision Making in Patients With Lung Cancer NCT05191485 | Sichuan Cancer Hospital and Research Institute | — |
| Recruiting | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) NCT05717803 | Fudan University | Phase 3 |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of NCT05558904 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Unknown | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma NCT05675033 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Pathogenic Variants in Genes Associated With Lung Adenocarcinoma NCT06181812 | Oscar Gerardo Arrieta Rodríguez | — |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplati NCT05198830 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma NCT05736991 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Suspended | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) NCT04929041 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Recruiting | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy NCT05537922 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | A Single-arm Exploratory Study of Neoadjuvant Therapy NCT05527808 | Jun Liu | N/A |
| Recruiting | Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenoca NCT05528458 | Samsung Medical Center | Phase 2 |
| Unknown | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions NCT05526573 | Azienda Sanitaria-Universitaria Integrata di Udine | — |
| Unknown | Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma NCT05400304 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Recruiting | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection NCT05517811 | University of Colorado, Denver | — |
| Unknown | The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. NCT05279521 | National Taiwan University Hospital | N/A |
| Unknown | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) NCT05794724 | Fudan University | — |
| Unknown | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) NCT05794711 | Fudan University | — |
| Completed | Intraoperative Frozen Section Pathology to Diagnose the IASLC Grades for Lung Adenocarcinoma (ECTOP-1014) NCT05794698 | Fudan University | — |
| Terminated | Milademetan in Advanced/Metastatic Solid Tumors NCT05012397 | Rain Oncology Inc | Phase 2 |
| Unknown | Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patie NCT05136014 | Central Hospital, Nancy, France | — |
| Not Yet Recruiting | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma NCT04965831 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Terminated | IBI188 Combination Therapy in Solid Tumors NCT04861948 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Active Not Recruiting | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lun NCT04625647 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Completed | Cios Mobile 3D Spin for Robotic Bronchoscopy NCT04740047 | Mayo Clinic | — |
| Enrolling By Invitation | Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma NCT06730477 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Terminated | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT04682431 | Ikena Oncology | Phase 1 |
| Terminated | A Study of PY314 in Subjects With Advanced Solid Tumors NCT04691375 | Ikena Oncology | Phase 1 |
| Unknown | TCM in the Treatment of Lung Adenocarcinoma NCT04482829 | Henan University of Traditional Chinese Medicine | N/A |
| Recruiting | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for P NCT04339218 | Institut Bergonié | Phase 3 |
| Unknown | Identify Prognostic Biomarkers of Lung Cancer NCT05010330 | RenJi Hospital | — |
| Completed | 18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma NCT04588064 | The First Affiliated Hospital of Xiamen University | N/A |
| Completed | Radiomics-based Prediction Model of Tumor Spread Through Air Space in Lung Adenocarcinoma NCT04893200 | University of Roma La Sapienza | — |
| Recruiting | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers NCT06255197 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm NCT04937283 | Shanghai Pulmonary Hospital, Shanghai, China | N/A |
| Recruiting | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm NCT05838053 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Unknown | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene NCT03905317 | Sun Yat-sen University | Phase 2 |
| Terminated | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma NCT03891173 | Helix BioPharma Corporation | Phase 2 |
| Completed | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma NCT03904563 | Sun Yat-sen University | Phase 2 |
| Unknown | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary No NCT04554875 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Unknown | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation NCT03486496 | Fujian Cancer Hospital | Phase 2 |
| Completed | Lung Nodule Prospective Database NCT03922828 | Singapore General Hospital | — |
| Completed | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection NCT03704870 | University Health Network, Toronto | Phase 2 |
| Unknown | Exhaled Breath Particles in Lung Cancer NCT05395611 | Lund University Hospital | — |
| Completed | Sleep State in Lung Cancer: A Retrospective Analysis NCT06953492 | Shanghai Zhongshan Hospital | — |
| Active Not Recruiting | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Sm NCT03391869 | M.D. Anderson Cancer Center | Phase 3 |
| Unknown | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma NCT03376737 | Henan Cancer Hospital | Phase 2 |
| Recruiting | Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cance NCT03199651 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | CAR T Cells in Mesothelin Expressing Cancers NCT03054298 | University of Pennsylvania | Phase 1 |
| Completed | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired R NCT03076164 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Unknown | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Contro NCT02951637 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma NCT02898857 | University Hospital, Montpellier | — |
| Unknown | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations Aft NCT02788058 | First People's Hospital of Hangzhou | Phase 2 |
| Unknown | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line T NCT02787447 | First People's Hospital of Hangzhou | Phase 2 |
| Unknown | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation NCT02737774 | Henan Cancer Hospital | Phase 2 |
| Completed | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treat NCT02759835 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test NCT02738684 | Southwest Hospital, China | — |
| Active Not Recruiting | Tumor Microenvironment NCT05982574 | University Hospital Heidelberg | — |
| Unknown | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-typ NCT02691871 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 |
| Completed | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (E NCT02980991 | Fudan University | Phase 2 |
| Terminated | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarc NCT02621333 | Henan Cancer Hospital | Phase 2 |
| Completed | Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy NCT02679443 | Post Graduate Institute of Medical Education and Research, Chandigarh | N/A |
| Unknown | Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma NCT02399566 | Hunan Province Tumor Hospital | Phase 4 |
| Completed | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression NCT03544814 | Shanghai Chest Hospital | Phase 2 |
| Completed | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarci NCT02093000 | Hoffmann-La Roche | — |
| Unknown | Blood Detection of EGFR Mutation For Iressa Treatment NCT02282267 | Peking University Cancer Hospital & Institute | N/A |
| Completed | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III NCT02186847 | NRG Oncology | Phase 2 |
| Completed | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Ce NCT01737502 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cance NCT02121925 | Myriad Genetic Laboratories, Inc. | — |
| Unknown | Molecular Analysis of 150 Lung Adenocarcinoma NCT02843711 | Hospices Civils de Lyon | — |
| Unknown | Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion NCT02011997 | The First Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Unknown | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas NCT01942629 | Rambam Health Care Campus | — |
| Completed | Whole-Exome Sequencing (WES) of Cancer Patients NCT02127359 | Dana-Farber Cancer Institute | — |
| Terminated | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. NCT01578551 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases NCT01578668 | Guangzhou Medical University | Phase 2 |
| Unknown | Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy NCT01482585 | Samsung Medical Center | — |
| Active Not Recruiting | Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small NCT01386385 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Prog NCT01294306 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma NCT01249066 | China Medical University Hospital | — |
| Unknown | Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma NCT01249053 | China Medical University Hospital | — |
| Terminated | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Rec NCT00955305 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" t NCT00716456 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage I NCT00334815 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurre NCT00950365 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non- NCT00126581 | National Cancer Institute (NCI) | Phase 2 |